Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Total revenues	$ 40,130	$ 22,546	$ 35,504
Operating expenses:
Cost of sales	18,081	415
Research and development	216,205	203,701	246,854
Selling, general and administrative	151,164	91,109	58,235
Total operating expenses	385,450	295,225	305,089
Loss from operations	(345,320)	(272,679)	(269,585)
Interest and other income (expense), net	13,516	(1,338)	1,533
Interest expense	(18,740)	(11,603)	(61)
Net loss	(350,544)	(285,620)	(268,113)
Net loss (income) attributable to noncontrolling interest (SRX Cardio)	321	(470)	(930)
Net loss attributable to Portola	$ (350,223)	$ (286,090)	$ (269,043)
Net loss per share attributable to Portola common stockholders:
Basic and diluted	$ (5.31)	$ (4.81)	$ (4.76)
Shares used to compute net loss per share attributable to Portola common stockholders:
Basic and diluted	66,017,330	59,508,156	56,480,647
Product Revenue, Net
Revenues:
Total revenues	$ 24,117
Collaboration and License Revenue
Revenues:
Total revenues	$ 16,013	$ 22,546	$ 35,504